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SUMMARY
The monopoly enjoyed by pharmaceutical manufacturers, resulting from the protection of intel-
lectual property, directly affects the price of medicinal products and thus their availability, especially in 
developing and least-developed countries. The aim of the article was to examine the provisions of the 
Agreement on Trade-Related Aspects of Intellectual Property Rights adopted under the World Trade 
Organization, an attempt to answer the question of whether it is possible to reconcile the protection 
of intellectual property with the human right to health.
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INTRODUCTION
The issue of intellectual property protection has been for years a subject of lively 
discussion between supporters and opponents of protection. The scale of emotions 
is well illustrated by a quote from “The Economist” magazine issue of 26 July 1851, 
which stated that: “Society would soon find out that patents rarely secure really 
good inventions and grant ordinary trivialities the significance of a discovery, and 
that there would be nothing good from patent law, no matter how finely written”1. 
Opponents of intellectual property protection believe that knowledge is a public 
1 See A. Wróbel, Handel lekami w regulacjach Światowej Organizacji Handlu, [in:] Ochrona 
zdrowia w stosunkach międzynarodowych, red. W. Lizak, A.M. Solarz, Warszawa 2013, p. 78.





good and should, therefore, not be subject to legal regulations. On the other hand, 
proponents of intellectual property protection point to the economic aspect, since, 
owing to the rights arising from the protection granted, it is profitable for companies 
to invest and often bear huge costs.
The conflict seems to be even more exacerbated when comparing these argu-
ments with the issue of health rights and access to medicines. Patents undoubtedly 
form the basis for progress in medicine. A company which discloses a pharmaceu-
tical formulation in the patent procedure is granted a monopoly on its production 
for a certain period of time. This compensates the company for the expenditure 
associated with the introduction of a new substance to the market. However, very 
often the monopoly of one company results in higher prices for medicines, which, 
as confirmed by World Bank analyses, makes them unavailable to poorer countries2.
In November 2001, the Committee on Economic, Social and Cultural Rights 
issued a statement referring to the relationship between human rights and intel-
lectual property rights3. What the Committee particularly points out to is that the 
regulation of intellectual property law must be compliant with human rights and 
this applies both to national and international laws, including the TRIPS Agreement. 
The approach to intellectual property rights related to human rights requires all 
stakeholders to be responsible for their obligations under international human rights 
law, in particular with regard to the adoption, interpretation and implementation of 
intellectual property systems. The Committee also stresses that trade agreements are 
not excluded from the obligation to comply with human rights, and that specialised 
international organisations should seek to play a positive role in the human rights 
protection process.
Intellectual property rights do not operate in an empty void: not only should they 
serve to protect private interests, but also, and above all, they should contribute to 
society as a whole4. The main challenge in the area of intellectual property protec-
tion in the area of public health is to find a solution that would, on the one hand, 
safeguard the interests of manufacturers and, on the other, guarantee the safety of 
patients. In view of the above, pharmaceutical patents inevitably generate tension 
between the right of citizens to health and well-being, and the exclusivity which 
primarily stimulates the development of new medicines5.
2 See World Development Report 2000/2001, World Bank, Washington.
3 Human Rights and Intellectual Property Issues: Statement by the Committee on Economic, 
Social and Cultural Rights, 26 November 2001, ONZ E/C.12/2001/15.
4 M. Barczewski, Prawa własności intelektualnej w Światowej Organizacji Handlu a dostęp 
do produktów leczniczych, Warszawa 2013, p. 87.
5 M.V. Hristova, Are Intellectual Property Rights Human Rights? Patent Protection and the 
Right to Health, “Journal of the Patent and Trademark Office Society” 2011, Vol. 93(3), p. 339.
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This article is to analyse the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) and to try to answer the question of whether it is possible 
to reconcile the protection of intellectual property with the human right to health.
CHARACTERISTICS OF THE RIGHT TO HEALTH AND THE 
INTELLECTUAL PROPERTY RIGHT
The right to health is one of the human rights enshrined in fundamental doc-
uments of universal and regional application. The first international agreement to 
formulate the right to health was the Constitution of the World Health Organization, 
adopted in 19466. Its preamble states that: “The enjoyment of the highest attainable 
standard of health is one of the fundamental rights of every human being without 
distinction of race, religion, political belief, economic or social condition”. Another 
document which stressed the right to medical care was the Universal Declaration of 
Human Rights, adopted by the United Nations General Assembly on 10 December 
1948 which, in Article 25 (1), states that: “Everyone has the right to a standard of 
living adequate for the health and well-being of himself and of his family, including 
food, clothing, housing and medical care and necessary social services, and the right 
to security in the event of unemployment, sickness, disability, widowhood, old age 
or other lack of livelihood in circumstances beyond his control […]”.
The most important provision is contained in Article 12 of the Internation-
al Covenant on Economic, Social and Cultural Rights7, which provides for the 
right of everyone to the enjoyment of the highest attainable standard of physical 
and mental health. Paragraph 2 lists the steps to be taken by the States Parties to 
achieve the full realization of this right: a) the provision for the reduction of the 
stillbirth-rate and of infant mortality and for the healthy development of the child; 
b) the improvement of all aspects of environmental and industrial hygiene; c) the 
prevention, treatment and control of epidemic, endemic, occupational and other 
diseases; d) the creation of conditions which would assure to all medical service 
and medical attention in the event of sickness. The Committee on Economic, Social 
and Cultural Rights stressed that the right to physical and mental health protection 
enshrined in the Covenant is not limited to the right to health care but must also be 
understood as the right to use a range of facilities, goods, services and conditions 
necessary to achieve the highest attainable standard of health, such as access to 
clean water, adequate sanitation and access to essential medicines8.
6 www.who.int/governance/eb/who_constitution_en.pdf [access: 10.11.2019].
7 www.ohchr.org/en/professionalinterest/pages/cescr.aspx [access: 10.11.2019].
8 M. Barczewski, op. cit., p. 187.





It is no coincidence that the instruments shaping universal standards of hu-
man rights protection also contain provisions that require the protection of public 
and private interests in the fields of creativity and knowledge9. Article 27 of the 
Universal Declaration of Human Rights stipulates that every person has the right 
to the protection of the moral and material interests resulting from any scientific, 
literary or artistic production of which he or she is the author. This right is also 
reaffirmed in Article 15 (1) of the International Covenant on Economic, Social and 
Cultural Rights.
Although intellectual property law and human rights have largely evolved 
separately, the extension of the intellectual property system to the health sector 
requires further consideration of the growing link between the right to health and 
the patentability of medicines10.
AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL 
PROPERTY RIGHTS
The basis for patent protection is made by the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) adopted as part of the World Trade 
Organization11. As B. Ziemblicki writes, this agreement is not based on non-discrim-
ination and free trade like GATT and GATS, but on the positive obligations of the 
parties in the form of minimum regulations and enforcement mechanisms12. Before 
the TRIPS Agreement entered into force, countries had the freedom to introduce 
and shape the patent protection adopted for their territories13. This usually resulted 
in many countries not patenting medicinal products. Instead, they manufactured or 
imported generic medicines, which are cheaper substitutes for patented products. 
Under the TRIPS Agreement, pursuant to Article 33, the term of protection ends 
with the expiration of a period of 20 years counted from the filing date14.
9 Ibidem, p. 182.
10 M.V. Hristova, op. cit., p. 340.
11 Agreement on Trade-Related Aspects of Intellectual Property Rights (as amended on 23 Janu- 
ary 2017), www.wto.org/english/docs_e/legal_e/31bis_trips_01_e.htm [access: 12.10.2019].
12 B. Ziemblicki, Ochrona praw człowieka w systemie Światowej Organizacji Handlu, Toruń 
2013, p. 199.
13 An example of this is the Paris Convention on the Protection of Industrial Property, which 
has allowed the member countries to exclude entire sectors from the possibility of patenting and 
individually setting the length of protection of intellectual property. See S. Joseph, Blame it on the 
WTO? A Human Rights Critique, Oxford 2011, p. 215; M. Barczewski, op. cit., p. 13.
14 It is worth noting that the countries of the European Union, the U.S. or Japan have provided 
for the possibility of extending the exclusivity of the use of medicinal products after the cessation of 
their patent protection. As M. du Vall rightly notes, the process of placing the medicinal product on 
the market takes 10 years on average, so the effective patent protection period is much shorter than for 
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The TRIPS preamble stresses “special needs of the least-developed country 
Members in respect of maximum flexibility in the domestic implementation of laws 
and regulations in order to enable them to create a sound and viable technological 
base”. It is commonly pointed out in the literature that many TRIPS provisions 
are imprecise, thus leaving room for broad interpretation, which is referred to as 
“constructive ambiguity”15. This solution is intended to help reconcile various, 
often extremely different, positions of negotiating countries.
Very often, the rationale for patent protection is the conviction that patents are 
privileges granted to the inventor by society and therefore they should be subject 
to restrictions that take into account important social goals, such as the need to 
ensure access to medicines16. Article 1 of the TRIPS Agreement shows that its 
provisions shape the minimum protection. This means that WTO Member States 
may provide in their legislation for a higher level of protection than that provided 
for in TRIPS. As noted by J. Barcik, rigorous regulation could discourage from 
signing TRIPS many developing countries seeking to access such patent-protected 
products as pharmaceuticals17. The objectives of the TRIPS Agreement, which 
should be taken into account during its interpretation18, are specified in Article 7: 
“The protection and enforcement of intellectual property rights should contribute 
to the promotion of technological innovation and to the transfer and dissemination 
of technology, to the mutual advantage of producers and users of technological 
knowledge and in a manner conducive to social and economic welfare, and to 
a balance of rights and obligations”. The principles of the TRIPS Agreement are 
set out in Article 8: “1. Members may, in formulating or amending their laws and 
regulations, adopt measures necessary to protect public health and nutrition, and to 
promote the public interest in sectors of vital importance to their socio-economic 
and technological development, provided that such measures are consistent with 
the provisions of this Agreement; 2. Appropriate measures, provided that they 
are consistent with the provisions of this Agreement, may be needed to prevent 
the abuse of intellectual property rights by right holders or the resort to practices 
which unreasonably restrain trade or adversely affect the international transfer of 
other inventions. See M. du Vall, [in:] System Prawa Prywatnego, t. 14A: Prawo własności przemy-
słowej, red. R. Skubisz, Warszawa 2012, pp. 136–137. In the WTO-held dispute between the European 
Communities and Canada on the protection of patent pharmaceutical products, it was assumed that the 
actual duration of the patent is between 8 and 12 years. See WT/DS114/R, paragraph 7.3.
15 M. Barczewski, op. cit., p. 73.
16 C.M. Ho, Access to Medicine on the Global Economy: International Agreements on Patents 
and Related Rights, Oxford 2011, p. 159.
17 J. Barcik, Międzynarodowe prawo zdrowia publicznego, Warszawa 2013, p. 31.
18 Article 31 (1) of the Vienna Convention on the law of treaties states that “A treaty shall be 
interpreted in good faith in accordance with the ordinary meaning to be given to the terms of the 
treaty in their context and in the light of its object and purpose”.





technology”. Therefore, the TRIPS Agreement strives to find a balance between 
the long-term goal of stimulating research into new inventions and the short-term 
goal of enabling people to use existing ones19.
Furthermore, the TRIPS Agreement provides for certain exceptions to patent-
ability once certain strict conditions are met. These include voluntary licensing, 
compulsory licensing and the so-called Bolar amendment. Article 27 (2) allows 
members to exclude from patentability inventions, the prevention within their ter-
ritory of the commercial exploitation of which is necessary to protect ordre public 
or morality, including to protect human, animal or plant life or health or to avoid 
serious prejudice to the environment. The condition for such an exclusion is that 
it is not made merely because the exploitation is prohibited by their law. Volun-
tary licenses allow the production of generic drugs in accordance with patent law. 
Pursuant to Article 28 of the TRIPS Agreement, “Patent owners shall also have 
the right to assign, or transfer by succession, the patent and to conclude licensing 
contracts”. It is worth pointing out, however, that the granting of a voluntary license 
depends solely on the goodwill of the patent owner.
On the other hand, Articles 30 and 31 of the TRIPS Agreement govern the 
possibility of excluding rights that are already protected by a patent. The first of 
them states that Members may provide limited exceptions to the exclusive rights 
conferred by a patent, provided that such exceptions do not unreasonably conflict 
with a normal exploitation of the patent and do not unreasonably prejudice the legit-
imate interests of the patent owner, taking account of the legitimate interests of third 
parties. The literature underlines that this is a special case, the purpose of which is 
to encourage the undertakings to manufacture substitute products. Where medicines 
are protected by patents, countries may lay down rules that allow, for example, the 
launch of tests and the adoption of decisions to allow substitutes even before the 
end of the protection period of the medicine concerned20. This provision is often 
called the regulatory provision or the Bolar provision and has been maintained as 
compatible with the TRIPS in the WTO Panel’s decision of 17 March 2000 on the 
assessment of the legality of the Canadian version of the Bolar exception21, which 
19 WTO Agreements & Public Health. A joint study by the WHO and the WTO Secretariat, WHO, 
WTO, 2002, p. 39.
20 B. Ziemblicki, op. cit., p. 201.
21 Roche Products, Inc. owned a patent for the active substance flurazepam with psychotropic 
properties, constituting a component of a drug for the treatment of insomnia, Dalmane. One year before 
the patent expiry, pharmaceutical company Bolar Pharmaceutical Col., Inc. began working to be able 
to manufacture this drug once the patent expires. Roche then accused Bolar of infringing the Roche’s 
patent right on the grounds that Bolar had conducted experimental research on the active substance 
of the patented drug. See Canada – patent protection of pharmaceutical products. Complaint by the 
European Communities and their Member States. Report of the Panel, WTO, Geneva 17.03.2000, 
WT/DS114/R.
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allows medicinal product manufacturers to use a protected active substance for the 
purpose of carrying out the registration procedure of the medicine concerned and 
obtaining during the term of patent protection a marketing authorisation once the 
patent is discontinued22.
Article 31 of the TRIPS Agreement goes even further by introducing compul-
sory licences, granted without the consent of the patent owner. Where the national 
legislation allows for other uses of the subject matter of a patent without the au-
thorisation of the patent right holder, such use will be permitted provided that prior 
efforts have been made to obtain authorisation from the right holder on reasonable 
commercial terms and conditions and that such efforts have not turned out to be 
successful within a reasonable period of time. Exceptionally, a Member State may 
waive this requirement in the case of a national emergency or other circumstances of 
extreme urgency or in cases of public non-commercial use. J. Barcik notes that the 
use of the expression “within a reasonable period of time” in this provision is highly 
vague, offering pharmaceutical corporations a lot of room for negotiation with the 
governments of developing countries23. At the same time, Article 31 of the TRIPS 
Agreement lays down several conditions that must be met cumulatively to consider 
such use lawful, including assessment of the legitimacy of the use based on individual 
merits of the case, a prior attempt to obtain authorisation from the right holder, the 
payment of adequate remuneration to the right holder, and the non-exclusivity and 
non-assignability of the use24.
ACTIONS TO IMPROVE ACCESS TO MEDICINES IN THE DOHA ROUND
It is very often argued by scholars in the field that patent protection in its current 
form is contrary to the right to health25. The WTO itself is attempting to improve 
this situation by amending existing regulations in order to make them more aimed 
at meeting public health needs.
On 9–13 November 2001, a Ministerial Conference took place in the capital of 
Qatar, Doha, during which the first round of multilateral trade negotiations at the 
forum of the World Trade Organisation started. The Ministerial Declaration pointed 
out that the main objective of the negotiation was to develop international trade 
22 A. Sztoldman, Korzystanie z chronionego wynalazku w celu rejestracji produktu leczniczego, 
Warszawa 2018, p. 26 ff.
23 J. Barcik, op. cit., p. 32.
24 B. Ziemblicki, op. cit., p. 201.
25 See P. Cullet, Patents Bill, TRIPS and right to health, “Economic and Political Weekly” 2001, 
October 27, pp. 4029–4051; C. Feng-Wu, Raising the right to health concerns within the framework 
of international intellectual property law, “Asian Journal of WTO & International Health Law and 
Policy” 2010, Vol. 5, pp. 141–205.





rules that take greater account than before of the interests of developing countries, 
thereby allowing for a wider integration of this group of countries into the WTO 
multilateral trade system26.
The particular importance of public health issues in the Doha Development 
Round was underlined by the separate Declaration on the TRIPS Agreement and 
Public Health. During the meeting of the TRIPS Council held in April 2001, the 
Zimbabwean representatives highlighted the problem of access to low-cost med-
icines and the lack of clear guidelines on how to interpret and apply TRIPS pro-
visions. In June 2001, another meeting of the TRIPS Council was held, which, as 
emphasized by K. Gamharter, was the first meeting in an international trade forum 
to formally address the discussion on access to medicinal products27.
On 14 November 2001, during the fourth WTO Ministerial Conference, the text 
of the Declaration on the TRIPS Agreement and Public Health (the Doha Decla-
ration)28 was adopted unanimously. Paragraph 1 thereof underlines that the parties 
“recognize the gravity of the public health problems afflicting many developing 
and least-developed countries, especially those resulting from HIV/AIDS, tuber-
culosis, malaria and other epidemics”. The declaration confirms “the need for the 
WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS 
Agreement) to be part of the wider national and international action to address these 
problems” (paragraph 2) and “recognize that intellectual property protection is 
important for the development of new medicines” (paragraph 3). Therefore, WTO 
members, while maintaining their obligations under the TRIPS Agreement, have 
the right to: a) apply customary rules of interpretation to TRIPS; b) independently 
grant compulsory licenses and set out the rules for granting them; c) determine 
emergency situations independently, while HIV/AIDS, malaria or tuberculosis can 
represent such situations; d) independently determine the rules for exhaustion of 
patentability of products29. Finally, WTO members confirmed the commitment of 
developed countries to promoting and supporting technology transfer to the poor-
est countries. One should agree with B. Ziemblicki that the declaration shows not 
only the WTO’s awareness of the problem of the relationship between intellectual 
property law and human rights, but also particular possible solutions and difficulties 
in their implementation30.
The Declaration on the TRIPS Agreement and Public Health became the point 
of departure for further actions of the TRIPS Council to find a solution to the prob-
26 M. Grącik-Zajączkowska, Unia Europejska i Stany Zjednoczone w Światowej Organizacji 
Handlu, Warszawa 2010, pp. 243–245.
27 K. Gamharter, Access to Affordable Medicines: Developing Responses under the TRIPS 
Agreement and EC Law, Berlin–Heidelberg 2004, p. 125.
28 WTO, Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2.
29 Ibidem, § 5.
30 B. Ziemblicki, op. cit., p. 205.
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lem of compulsory licenses31. The system was built in two stages. First, in 2003, 
the WTO General Council issued a decision on the implementation of paragraph 6 
of the Doha Declaration32. This decision, also known as “the waiver decision”33, 
provided for a waiver of the obligation to comply with Article 31 (f) the TRIPS 
Agreement, which allows authorisation to use the subject matter of a patent with-
out the consent of the right holder only if issued for the purpose of supplying the 
internal market of a Member State.
The second decision was adopted by the WTO General Council on 6 December 
2005 and submitted to the members for approval34. The protocol is an amendment 
to the TRIPS Agreement. This is the first multilateral treaty amendment agreed 
by WTO members since the entry into force of the WTO Agreement in 1995. The 
purpose of this regulation is to permanently incorporate in the TRIPS Agreement 
additional possibilities to grant compulsory licenses for the export of medicines. 
As a result, a company who is not the owner of a patent will be able to manufacture 
and sell substitutes of medicines covered by patent protection where a situation of 
a threat to public health occurs in an importing country.
The system became a permanent part of the Agreement on 23 January 2017, 
following the acceptance of the Protocol by two-thirds of the members35. So far, 
the mechanism established under the WTO Decision of 30 August 2003 and the 
Protocol to the TRIPS Agreement was used only once in 2007 by the Canadian 
company Apotex, the entity responsible for patents for the production of the generic 
drug TriAvir used in the treatment of AIDS. The company has agreed to supply to 
Rwanda a total of 260,000 packages at the production price.
One should point to yet another problem with the protection of intellectual 
property, namely, as statistics show, research in the pharmaceutical sector mainly 
involves diseases the treatment of which gives the greatest profits, i.e. diseases 
most occurring in rich countries36. This means that in the event of certain diseases, 
31 A. Wróbel, op. cit., p. 86.
32 Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public 
health, Decision of the General Council of 30 August 2003, General Council, WT/L/540 and Corr. 1, 
www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm [access: 23.10.2019].
33 J. Barcik, op. cit., p. 35.
34 Amendment of the TRIPS Agreement, 6 December 2005. The amendment consists in inserting 
Article 31bis following Article 31.
35 According to the WTO Agreement, a Member formally accepts the Protocol by depositing 
what is referred to as an instrument of acceptance for the Protocol with the Director General of the 
WTO. Members who have not yet done so, may accept the Protocol until 31 December 2019 or such 
later date as may be decided by the Ministerial Conference. See: How to accept the Protocol Amending 
the TRIPS Agreement. Background information for Members on procedures, www.wto.org/english/
tratop_e/trips_e/accept_e.htm [access: 12.10.2019].
36 According to the Commission of Intellectual Property Rights, less than 5% of the total money 
allocated globally to research and development of new drugs is spent on diseases affecting developing 





other incentives for innovation should be sought than the possibility of patenting 
a drug37. In response, T. Pogge proposed an alternative programme of encouraging 
pharmaceutical research, involving countries that would contribute to the Health 
Impact Fund from which inventors of new pharmaceuticals are to be paid38.
CONCLUSION
Despite the fact that the TRIPS Agreement seems to guarantee great flexibility, 
many of the issues arising from its provisions raise controversy. The TRIPS Agree-
ment in its current form prevents poor countries from buying the best medicines. Is 
it possible to reconcile the interests of companies with the right of people, especially 
the poorest, to health?
J. Tobin points out that the right to health should be used as a tool for interpre-
tation of the TRIPS Agreement. Consequently, where an unresolvable normative 
conflict arises, it is necessary to ensure that any interference of the protection of 
intellectual property into the right of access to medicinal products is justified, nec-
essary and proportionate39. In addition, there are flexible and adaptive measures 
under the TRIPS Agreement itself, such as compulsory licences to be used by the 
WTO Member States to increase access to medicinal products40.
The High Commissioner’s Report presents an example of the use of authorised 
strategies in the fight against HIV/AIDS by the Brazilian government between 1997 
and 200141. The Ministry of Health of Brazil developed a treatment consisting of 
twelve different pharmaceuticals, seven of which were produced in Brazil and the 
remaining five were imported. Two of these five imported were protected with 
patents in Brazil. The purchase of two patented drugs consumed 36% of the price 
of all the twelve drugs. For this reason, the Brazilian government was looking 
for methods to encourage the international pharmaceutical industry to enter into 
negotiations on drug sales, considering the purchasing power of the market. The 
introduction of compulsory licence provisions allowed Brazil to obtain favourable 
conditions for the purchase of medicines and thus increase the availability of HIV/
countries. For more details, see P. Ranjan, Understanding the Conflicts between the TRIPS Agreement 
and the Humam Right to Health, “Journal of World Investment & Trade” 2008, Vol. 9(6), DOI: https://
doi.org/10.1163/221190008X00278, pp. 551–570.
37 B. Ziemblicki, op. cit., p. 204.
38 S. Joseph, op. cit., p. 240.
39 M. Barczewski, op. cit., p. 204. 
40 See also H. Hestermeyer, Human Rights and the WTO. The Case of Patents and Access to 
Medicines, Oxford 2007.
41 Report of High Commissioner “The impact of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights on Human Rights”, E/CN.4/Sub.2/2001/12.
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AIDS drugs. Brazil’s example shows that the TRIPS Agreement gives states the 
instruments to effectively struggle for the health of their citizens. Nonetheless, 
these measures play only a supportive role and do not constitute a panacea for the 
challenges faced by global access to medicines.
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STRESZCZENIE
Monopol przysługujący producentom leków, wynikający z ochrony własności intelektualnej, 
wpływa bezpośrednio na cenę produktów leczniczych, a co za tym idzie na ich dostępność, szczegól-
nie w krajach rozwijających się i najmniej rozwiniętych. Celem artykułu była analiza postanowień 
porozumienia w sprawie handlowych aspektów praw własności intelektualnej, przyjętego w ramach 
Światowej Organizacji Handlu, a także próba odpowiedzi na pytanie, czy możliwe jest pogodzenie 
ochrony własności intelektualnej z prawem człowieka do zdrowia.
Słowa kluczowe: Światowa Organizacja Handlu; prawo do zdrowia; ochrona własności intelek-
tualnej; porozumienie TRIPS; ochrona patentowa
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